Cargando…

Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer

We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, K, Yamaguchi, T, Ishihara, T, Sudo, K, Kato, H, Saisho, H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361295/ https://www.ncbi.nlm.nih.gov/pubmed/16721372 http://dx.doi.org/10.1038/sj.bjc.6603168

Ejemplares similares

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
por: Nakamura, K, et al.
Publicado: (2005)

A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
por: Nakai, Y, et al.
Publicado: (2012)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
por: Kullmann, F, et al.
Publicado: (2009)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer
por: Millar, J, et al.
Publicado: (2005)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ohkawa, S, et al.
Publicado: (2015)

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
por: Okusaka, T, et al.
Publicado: (2004)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Kafri, Zyad, et al.
Publicado: (2012)

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
por: Stathopoulos, G P, et al.
Publicado: (2006)

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
por: Blackstock, A W, et al.
Publicado: (2006)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients
por: Corrie, P, et al.
Publicado: (2002)

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
por: Reni, M, et al.
Publicado: (2006)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer
por: Tan, S-B, et al.
Publicado: (2002)

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
por: Choy, Edwin, et al.
Publicado: (2018)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial
por: Ichinose, Y, et al.
Publicado: (2005)

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
por: Michael, M, et al.
Publicado: (2009)

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
por: Ko, A H, et al.
Publicado: (2013)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
por: Wilkowski, R, et al.
Publicado: (2009)

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
por: Hamada, T, et al.
Publicado: (2014)

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
por: Yoo, C, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study
por: Adamo, V, et al.
Publicado: (2008)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
por: Cook, Natalie, et al.
Publicado: (2018)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lk4nitbtopiplkt4u8fd58rsem